1:38 PM
Mar 08, 2018
 |  BC Extra  |  Financial News

Clearside, G1 price upsized follow-ons

Ophthalmology company Clearside Biomedical Inc. (NASDAQ:CLSD) and cancer company G1 Therapeutics Inc. (NASDAQ:GTHX) each priced bumped-up follow-ons on the back of positive data, raising a total of $185.3 million.

Clearside raised $85 million through the sale of 6.5 million shares at $13 in a follow-on underwritten by J.P. Morgan, Cowen, Stifel, Needham and Wedbush. The price is a small premium...

Read the full 279 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >